Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...

The Big Money Show' panel discusses President Donald Trump's plan to bring drug manufacturing back to the U.S.

Eli Lilly is a veteran of the industry ... Though tariffs may be hard to come back from, as the CEO argued, the company is about as well-positioned as any of its peers in the industry to handle ...

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning. The Trump administration ...

Related Experimental Eli Lilly weight loss drug proves promising ... branded medications," Mochi's statement said. Mochi Health CEO Myra Ahmad told CNBC in March it planned to keep selling ...

Eli Lilly is suing four telemedicine companies selling ... In its filing, Lilly claimed Mochi CEO Myra Ahmad is not a licensed physician “Mochi Health and its unlicensed owners exercise undue ...

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday ... compounded versions of tirzepatide. In March, Mochi CEO Myra Ahmad told CNBC that she wasn’t worried about ...

A new daily weight-loss pill could be just as effective as the popular injectables that help patients lower their blood sugar and lose unwanted weight. "I think we're really at the beginning of a ...